CA2451885A1 - Method and material for treating immune diseases - Google Patents
Method and material for treating immune diseases Download PDFInfo
- Publication number
- CA2451885A1 CA2451885A1 CA002451885A CA2451885A CA2451885A1 CA 2451885 A1 CA2451885 A1 CA 2451885A1 CA 002451885 A CA002451885 A CA 002451885A CA 2451885 A CA2451885 A CA 2451885A CA 2451885 A1 CA2451885 A1 CA 2451885A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- galectin
- modified pectin
- administering
- animal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims description 63
- 239000000463 material Substances 0.000 title abstract description 53
- 208000026278 immune system disease Diseases 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 47
- 229920001277 pectin Polymers 0.000 claims abstract description 43
- 239000001814 pectin Substances 0.000 claims abstract description 43
- 235000010987 pectin Nutrition 0.000 claims abstract description 43
- 102000007563 Galectins Human genes 0.000 claims abstract description 34
- 108010046569 Galectins Proteins 0.000 claims abstract description 34
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 14
- 230000028993 immune response Effects 0.000 claims abstract description 10
- 229930182830 galactose Natural products 0.000 claims abstract description 8
- 102000000802 Galectin 3 Human genes 0.000 claims abstract description 7
- 108010001517 Galectin 3 Proteins 0.000 claims abstract description 7
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims abstract description 7
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims abstract description 7
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical group C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims abstract description 6
- 102000000795 Galectin 1 Human genes 0.000 claims abstract description 5
- 108010001498 Galectin 1 Proteins 0.000 claims abstract description 5
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims abstract description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims abstract description 4
- 108010038196 saccharide-binding proteins Proteins 0.000 claims abstract description 3
- 241001465754 Metazoa Species 0.000 claims description 14
- 208000023275 Autoimmune disease Diseases 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 7
- 229920002230 Pectic acid Polymers 0.000 claims description 5
- 210000004027 cell Anatomy 0.000 claims description 5
- 230000001419 dependent effect Effects 0.000 claims description 5
- 239000010318 polygalacturonic acid Substances 0.000 claims description 4
- 125000000089 arabinosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)CO1)* 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000022461 Glomerular disease Diseases 0.000 claims description 2
- 229910052798 chalcogen Inorganic materials 0.000 claims description 2
- 150000001787 chalcogens Chemical class 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 231100000852 glomerular disease Toxicity 0.000 claims description 2
- 150000003567 thiocyanates Chemical class 0.000 claims description 2
- 150000003573 thiols Chemical class 0.000 claims description 2
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 230000000035 biogenic effect Effects 0.000 claims 1
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
- 229920005615 natural polymer Polymers 0.000 abstract description 2
- 229920001059 synthetic polymer Polymers 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 150000001720 carbohydrates Chemical class 0.000 description 8
- 235000014633 carbohydrates Nutrition 0.000 description 8
- 235000000346 sugar Nutrition 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 3
- FJEKYHHLGZLYAT-FKUIBCNASA-N galp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(O)=O)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)[C@@H](C)O)C(C)C)C1=CNC=N1 FJEKYHHLGZLYAT-FKUIBCNASA-N 0.000 description 3
- 230000008105 immune reaction Effects 0.000 description 3
- 230000000899 immune system response Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 235000021309 simple sugar Nutrition 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 241000207199 Citrus Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 239000009194 citrus pectin Substances 0.000 description 1
- 229940040387 citrus pectin Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/732—Pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30036001P | 2001-06-22 | 2001-06-22 | |
| US60/300,360 | 2001-06-22 | ||
| US10/176,022 US20030004132A1 (en) | 2001-06-22 | 2002-06-20 | Method and material for treating immune diseases |
| US10/176,022 | 2002-06-20 | ||
| PCT/US2002/019886 WO2003000195A2 (en) | 2001-06-22 | 2002-06-21 | Method and material for treating immune diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2451885A1 true CA2451885A1 (en) | 2003-01-03 |
Family
ID=26871794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002451885A Abandoned CA2451885A1 (en) | 2001-06-22 | 2002-06-21 | Method and material for treating immune diseases |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20030004132A1 (https=) |
| EP (1) | EP1408989A2 (https=) |
| JP (1) | JP2004536825A (https=) |
| CN (1) | CN100558368C (https=) |
| BR (1) | BR0210547A (https=) |
| CA (1) | CA2451885A1 (https=) |
| IL (1) | IL159462A0 (https=) |
| WO (1) | WO2003000195A2 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040223971A1 (en) * | 2003-04-07 | 2004-11-11 | Glycogenesys, Inc. | Composition and uses of galectin antagonists |
| DE602004014485D1 (de) | 2003-04-07 | 2008-07-31 | Prospect Therapeutics Inc | Zusammensetzung und anwendungen von galectin-antagonisten |
| US20050158321A1 (en) * | 2003-12-17 | 2005-07-21 | Entelos, Inc. | Treatment of rheumatoid arthritis with galectin-3 antagonists |
| WO2005095463A1 (en) | 2004-03-26 | 2005-10-13 | Glycogenesys, Inc. | Modified pectins, compositions and methods related thereto |
| US8728742B2 (en) * | 2011-03-17 | 2014-05-20 | Critical Care Diagnostics, Inc. | Methods predicting risk of an adverse clinical outcome |
| MX363923B (es) | 2011-12-28 | 2019-04-08 | Galectin Therapeutics Inc | Composicion de farmaco de carbohidrato novedoso para el tratamiento de enfermedades humanas. |
| CA2875979C (en) * | 2012-06-06 | 2021-01-26 | Galectin Therapeutics, Inc. | Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase |
| AU2013315019B2 (en) | 2012-09-17 | 2017-06-01 | Galectin Therapeutics, Inc. | Method for enhancing specific immunotherapies in cancer treatment |
| DK2906227T3 (en) | 2012-10-10 | 2018-12-10 | Galectin Therapeutics Inc | GALACTOSE-CONTAINING CARBOHYDRATE COMPOUNDS FOR THE TREATMENT OF DIABETIC Nephropathy |
| US12390486B2 (en) | 2012-12-20 | 2025-08-19 | Henry Ford Health System | Method for treating diastolic heart failure by inhibiting galectin-3 |
| JP2016507503A (ja) | 2012-12-20 | 2016-03-10 | ヘンリー フォード ヘルス システム | ガレクチン−３を阻害することによる拡張期心不全を治療する方法 |
| US9339515B2 (en) | 2013-02-20 | 2016-05-17 | Galectin Therapeutics, Inc. | Method for treatment of pulmonary fibrosis |
| CA3088736A1 (en) * | 2018-01-21 | 2019-07-25 | Rensselaer Polytechnic Institute | Method of treating galectin-3 dependent disorders |
| US20210138080A1 (en) | 2018-06-29 | 2021-05-13 | Glykos Biomedical Oy | Conjugates |
| WO2021123506A1 (en) | 2019-12-18 | 2021-06-24 | Glykos Biomedical Oy | Stabile conjugate |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5490991A (en) * | 1986-07-03 | 1996-02-13 | Advanced Magnetics, Inc. | Directed delivery of radioprotectants using a receptor specific carrier |
| AU638146B2 (en) * | 1990-06-27 | 1993-06-17 | Dainippon Ink And Chemicals Inc. | Alkylated oligosaccharides and acetyl derivatives of the same |
| US5498702A (en) * | 1993-12-16 | 1996-03-12 | California Natural Products | Treated pectinic acid process and product |
| US5834442A (en) * | 1994-07-07 | 1998-11-10 | Barbara Ann Karmanos Cancer Institute | Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin |
| US5831052A (en) * | 1997-05-07 | 1998-11-03 | Incyte Pharmaceuticals, Inc. | New human translocation associated protein |
| US6258383B1 (en) * | 1998-08-14 | 2001-07-10 | Lactoferrin Products Company | Dietary supplement combining colostrum and lactoferrin in a mucosal delivery format |
| US6500807B1 (en) * | 1999-02-02 | 2002-12-31 | Safescience, Inc. | Modified pectin and nucleic acid composition |
| US6680306B2 (en) * | 2001-06-21 | 2004-01-20 | Glycogenesys, Inc. | Method for enhancing the effectiveness of cancer therapies |
-
2002
- 2002-06-20 US US10/176,022 patent/US20030004132A1/en not_active Abandoned
- 2002-06-21 JP JP2003506641A patent/JP2004536825A/ja active Pending
- 2002-06-21 IL IL15946202A patent/IL159462A0/xx unknown
- 2002-06-21 CN CNB028160916A patent/CN100558368C/zh not_active Expired - Fee Related
- 2002-06-21 EP EP02749642A patent/EP1408989A2/en not_active Withdrawn
- 2002-06-21 BR BR0210547-0A patent/BR0210547A/pt not_active IP Right Cessation
- 2002-06-21 CA CA002451885A patent/CA2451885A1/en not_active Abandoned
- 2002-06-21 WO PCT/US2002/019886 patent/WO2003000195A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003000195A2 (en) | 2003-01-03 |
| JP2004536825A (ja) | 2004-12-09 |
| CN100558368C (zh) | 2009-11-11 |
| US20030004132A1 (en) | 2003-01-02 |
| BR0210547A (pt) | 2004-05-25 |
| WO2003000195A3 (en) | 2003-03-20 |
| IL159462A0 (en) | 2004-06-01 |
| EP1408989A2 (en) | 2004-04-21 |
| CN1543352A (zh) | 2004-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2451885A1 (en) | Method and material for treating immune diseases | |
| US6680306B2 (en) | Method for enhancing the effectiveness of cancer therapies | |
| Bajaj et al. | Zwitterionic chitosan derivative, a new biocompatible pharmaceutical excipient, prevents endotoxin-mediated cytokine release | |
| Dhal et al. | Functional polymers as therapeutic agents: concept to market place | |
| AU2002320140A1 (en) | Method for enhancing the effectiveness of cancer therapies | |
| SK288087B6 (sk) | Pharmaceutical or dietetic preparation and use antiadhesive carbohydrates for production of medicament | |
| US20070141101A1 (en) | Method for stimulating angiogenesis and wound healing | |
| SK459890A3 (en) | USE OF HYALURONIC ACID, THE SALTS THEREOF AND ANALOGUES FORì (54) PRODUCING A THERAPEUTIC AGENT TO TREAT DISEASES OR CONDIT | |
| US7741311B2 (en) | Composition and method for treating occlusive vascular diseases, nerve regeneration, and wound healing | |
| Motokawa et al. | Selectively crosslinked hyaluronic acid hydrogels for sustained release formulation of erythropoietin | |
| EP2025687A1 (en) | Process for the preparation of heparanase-inhibiting sulfated hyaluronates and products obtained thereby | |
| CA2875979A1 (en) | Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase | |
| Nakamura et al. | Controlled release of fibroblast growth factor‐2 from an injectable 6‐O‐desulfated heparin hydrogel and subsequent effect on in vivo vascularization | |
| Niu et al. | Natural glycan derived biomaterials for inflammation targeted drug delivery | |
| JP2004536825A5 (https=) | ||
| Sahoo et al. | Chitosan: The most valuable derivative of chitin | |
| AU2002320141A1 (en) | Method and material for treating immune diseases | |
| Dumitriu et al. | Hydrogels as support for drug delivery systems | |
| Akoulina et al. | Current state of research on the mechanisms of biological activity of alginates | |
| Ngo et al. | Chitosan and its derivatives as potential biomaterials | |
| Singh et al. | Chitosan hydrogel: Its applications in medicine and dentistry | |
| Balazs et al. | Interaction of amino sugars and amino sugar-containing macromolecules with viruses, cells, and tissues | |
| JPWO2000059967A1 (ja) | グリコサミノグリカン機能化高分子及びそれを用いた医療器具並びに医薬 | |
| Carrabs | Role of microvesicles in gonarthrosis and their modulation by hyaluronic acid administered in viscosupplementation for the rational development of innovative medical devices | |
| Ngo | Chitin, Chitosan, and Their Derivatives against Oxidative Stress and Inflammation, and Some Applications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |